Zacks Research Has Bearish Outlook for BDX FY2025 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research reduced their FY2025 EPS estimates for Becton, Dickinson and Company in a research note issued to investors on Monday, December 16th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $14.39 for the year, down from their previous estimate of $14.43. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2025 earnings at $4.25 EPS, Q2 2026 earnings at $3.83 EPS, Q3 2026 earnings at $4.01 EPS, Q4 2026 earnings at $4.49 EPS and FY2026 earnings at $15.51 EPS.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the company posted $3.42 EPS. The firm’s revenue was up 6.9% on a year-over-year basis.

Several other equities analysts also recently commented on BDX. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Stock Performance

BDX opened at $227.68 on Thursday. The company has a 50 day simple moving average of $229.88 and a two-hundred day simple moving average of $233.19. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a market cap of $65.83 billion, a P/E ratio of 38.33, a PEG ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 2,838 shares of Becton, Dickinson and Company stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the sale, the executive vice president now directly owns 6,141 shares in the company, valued at approximately $1,371,469.53. This trade represents a 31.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. The trade was a 4.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,959 shares of company stock worth $1,764,340. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in BDX. Lord Abbett & CO. LLC increased its position in Becton, Dickinson and Company by 0.5% during the 3rd quarter. Lord Abbett & CO. LLC now owns 195,858 shares of the medical instruments supplier’s stock valued at $47,221,000 after purchasing an additional 1,022 shares during the period. Copley Financial Group Inc. bought a new stake in Becton, Dickinson and Company during the third quarter valued at about $457,000. Oddo BHF Asset Management Sas bought a new stake in Becton, Dickinson and Company during the third quarter valued at about $522,000. Peapack Gladstone Financial Corp grew its stake in Becton, Dickinson and Company by 2.1% in the third quarter. Peapack Gladstone Financial Corp now owns 101,600 shares of the medical instruments supplier’s stock valued at $24,497,000 after purchasing an additional 2,057 shares during the last quarter. Finally, Synovus Financial Corp lifted its position in Becton, Dickinson and Company by 9.8% during the third quarter. Synovus Financial Corp now owns 9,017 shares of the medical instruments supplier’s stock valued at $2,174,000 after acquiring an additional 808 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.